Journal
VETERINARY AND COMPARATIVE ONCOLOGY
Volume 20, Issue 3, Pages 602-612Publisher
WILEY
DOI: 10.1111/vco.12813
Keywords
anti-CD40 antibody; dogs; immunotherapy; interleukin-2; soft tissue sarcoma
Categories
Funding
- Selvax Pty Ltd
Ask authors/readers for more resources
Human and canine sarcomas are challenging soft tissue malignancies with high recurrence and metastasis rates. In a study using genetically identical mice, intra-tumoral delivery of IL-2 and an anti-CD40 antibody showed promising curative responses. The same approach was then tested in domestic dogs with naturally occurring sarcomas, resulting in tumor regression and minimal side effects. These findings provide encouraging proof-of-concept data for developing immunotherapeutic strategies in both veterinary and human medicine.
Human and canine sarcomas are difficult to treat soft tissue malignancies with an urgent need for new improved therapeutic options. Local recurrence rates for humans are between 10%-30%, and 30%-40% develop metastases. Outcomes for dogs with sarcoma vary with grade but can be similar. Pet dogs share the human environment and represent human cancer with genetic variation in hosts and tumours. We asked if our murine studies using genetically identical mice and cloned tumour cells were translatable to larger, genetically diverse domestic dogs with naturally occurring tumours, to (i) develop a canine cancer therapeutic, and (ii) to use as a translational pathway to humans. Our murine studies showed that intra-tumoral delivery of interleukin-2 (IL-2) plus an agonist anti-CD40 antibody (Ab) induces long-term curative responses ranging from 30% to 100%, depending on tumour type. We developed an agonist anti-canine-CD40 Ab and conducted a phase I dose finding/toxicology 3 + 3 clinical trial in dogs (n = 27) with soft tissue sarcomas on account of suitability for intratumoral injection and straightforward monitoring. Dogs were treated with IL-2 plus anti-CD40 antibody for 2 weeks. Three dose levels induced tumour regression with minimal side effects, measured by monitoring, haematological and biochemical assays. Importantly, our mouse and canine studies provide encouraging fundamental proof-of-concept data upon which we can develop veterinary and human immunotherapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available